JP2004500380A5 - - Google Patents

Download PDF

Info

Publication number
JP2004500380A5
JP2004500380A5 JP2001559460A JP2001559460A JP2004500380A5 JP 2004500380 A5 JP2004500380 A5 JP 2004500380A5 JP 2001559460 A JP2001559460 A JP 2001559460A JP 2001559460 A JP2001559460 A JP 2001559460A JP 2004500380 A5 JP2004500380 A5 JP 2004500380A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cell proliferation
rheumatoid arthritis
treating rheumatoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001559460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004500380A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/004095 external-priority patent/WO2001060363A1/en
Publication of JP2004500380A publication Critical patent/JP2004500380A/ja
Publication of JP2004500380A5 publication Critical patent/JP2004500380A5/ja
Pending legal-status Critical Current

Links

JP2001559460A 2000-02-15 2001-02-08 レフルノミドの合成方法 Pending JP2004500380A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18263500P 2000-02-15 2000-02-15
PCT/US2001/004095 WO2001060363A1 (en) 2000-02-15 2001-02-08 A method for synthesizing leflunomide

Publications (2)

Publication Number Publication Date
JP2004500380A JP2004500380A (ja) 2004-01-08
JP2004500380A5 true JP2004500380A5 (enExample) 2006-01-05

Family

ID=22669359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001559460A Pending JP2004500380A (ja) 2000-02-15 2001-02-08 レフルノミドの合成方法

Country Status (18)

Country Link
US (2) US6723855B2 (enExample)
EP (1) EP1257270B1 (enExample)
JP (1) JP2004500380A (enExample)
KR (1) KR20020072312A (enExample)
AT (1) ATE292966T1 (enExample)
AU (1) AU2001234943A1 (enExample)
CA (1) CA2400290A1 (enExample)
CZ (1) CZ20023024A3 (enExample)
DE (1) DE60110043T2 (enExample)
ES (1) ES2237553T3 (enExample)
HR (1) HRP20020671A2 (enExample)
HU (1) HUP0301865A3 (enExample)
IL (1) IL151196A0 (enExample)
PL (1) PL366088A1 (enExample)
SK (1) SK12992002A3 (enExample)
WO (1) WO2001060363A1 (enExample)
YU (1) YU61602A (enExample)
ZA (1) ZA200206494B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0987256T3 (da) * 1997-08-08 2002-02-11 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
JP2003517011A (ja) * 1999-12-16 2003-05-20 テバ ファーマシューティカル インダストリーズ リミティド レフルノミドの新規な製法及び新しい結晶形態
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
WO2003042193A1 (en) * 2001-11-09 2003-05-22 Geneva Pharmaceuticals, Inc. Process for preparing 5-methylisoxazole-4-carboxylic-(4'-trifluoromethyl)-anilide
DK1631291T3 (da) * 2003-05-27 2009-11-02 Robert P Haegerkvist Anvendelse af tyrosinkinaseinhibitorer til behandling af diabetes
EP1694308A1 (en) * 2003-10-30 2006-08-30 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
DE102005017592A1 (de) * 2005-04-16 2006-10-19 Lindner, Jürgen, Dr. med. Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem
WO2007086076A2 (en) * 2006-01-24 2007-08-02 Unichem Laboratories Limited An improved process for preparation of leflunomide
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
KR101547880B1 (ko) 2009-09-18 2015-08-27 사노피 향상된 안정성을 갖는 (ｚ)-2-시아노-3-하이드록시-부트-2-엔산-(4''-트리플루오로메틸페닐)-아미드 정제 제형
CN102002009B (zh) * 2010-10-18 2012-11-07 齐鲁制药有限公司 一种5-甲基异恶唑-4-甲酰氯的制备方法
AU2016280243B2 (en) * 2015-06-17 2020-12-03 Biocon Limited A novel process for the preparation of teriflunomide
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
GB8619432D0 (en) 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
JP2995086B2 (ja) * 1990-05-18 1999-12-27 ヘキスト・アクチエンゲゼルシヤフト イソオキサゾール−４−カルボキサミド類およびヒドロキシアルキリデンシアノアセトアミド類を含有する製剤
ATE174218T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 1 beta
US5610173A (en) 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
DK0987256T3 (da) * 1997-08-08 2002-02-11 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
JP2003517011A (ja) * 1999-12-16 2003-05-20 テバ ファーマシューティカル インダストリーズ リミティド レフルノミドの新規な製法及び新しい結晶形態

Similar Documents

Publication Publication Date Title
JP2002533216A5 (enExample)
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
JP2004500380A5 (enExample)
HUP0401293A3 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
JP2006501215A5 (enExample)
ZA200208489B (en) Salt-sensitive, water-dispersible polymer composition.
IL162316A0 (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition t
AU2003265589A8 (en) Process for the preparation of 1,1,1,2,2-pentafluoroethane
ZA200702523B (en) Process for the purification of 1,4-butanediol
MXPA03010019A (es) COMPOSICIoN PARA TRATAR EL ESTREnIMIENTO INDUCIDO POR FaRMACOS CON 15-CETO-PROSTAGLANDINAS.
AU2003288023A1 (en) Process for the manufacture of 1,2-epoxy-3-chloropropane
ZA200206808B (en) Endoparasiticidal gel composition.
JP2004518665A5 (enExample)
ZA200309514B (en) Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives.
TW200512207A (en) Substituted 3-(2, 5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases
AU2003210812A1 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders
MXPA02004860A (es) 3-(4,5-dihdroisoxazol-5-il) benzoilpirazoles.
EP1565448A4 (en) PROCESS FOR THE PREPARATION OF 10H-DIBENZOçB, F] ç1,4] THIAZEPIN-11-ON
ZA200306629B (en) Polymer modified gypsum composition.
JP2003284553A5 (enExample)
EG23417A (en) Process for the preparation 7 a-methylsteroids.
AU2003223992A1 (en) Solid stabilizer composition, the production and the use thereof
MXPA03005965A (es) Composicion farmaceutica que contiene citalopram.
ZA200110500B (en) Pharmaceutical composition.
AU2003235132A1 (en) Honey, novel honey composition and process for producing the same